EN

Login Register Online

Academic Achievement

Home
About
Academic Achievement

2023 Academic Publications
A New Option in Sperm Testing: The Potential of Taiwan-Made LensHooke® X1 PRO in Fertility Assessment
Presented by NUWA Fertility at the 2023 Taiwan Society for Reproductive Medicine (TSRM)

At the 2023 TSRM annual meeting, NUWA Fertility presented a study evaluating the performance of the Taiwan-made LensHooke® X1 PRO, a new computer-assisted semen analysis (CASA) system.
The results showed a high correlation between the X1 PRO and traditional manual microscopic semen analysis, suggesting strong potential for clinical use as a reliable alternative diagnostic tool.

Background: Enhancing the Objectivity and Efficiency of Semen Analysis

Semen analysis is a crucial component of evaluating male fertility.
While traditional manual microscopic analysis is widely accepted and considered accurate, it is subject to operator variability and subjective interpretation.

The emergence of CASA (Computer-Assisted Semen Analysis) systems aims to improve both efficiency and objectivity. This study assessed the reliability of the LensHooke® X1 PRO, comparing its results with those of manual semen analysis.

Methods: Evaluating the Consistency, Sensitivity, and Accuracy of X1 PRO
The research team compared semen parameters measured by the LensHooke® X1 PRO CASA system and manual microscopic semen analysis, assessing: Correlation, Consistency, Sensitivity, Specificity, Overall accuracy.

Key semen parameters such as sperm concentration, motility, and morphology were rigorously analyzed to determine performance alignment between the two methods.

Results: High Agreement Between LensHooke® X1 PRO and Manual Analysis
The study found that the LensHooke® X1 PRO showed strong consistency with manual semen analysis across multiple semen quality parameters.

Notably, at specific diagnostic thresholds, the X1 PRO demonstrated high sensitivity, specificity, and accuracy, indicating that it is reliable for identifying abnormal semen samples.

Clinical Implications: X1 PRO as a Promising Alternative for Semen Diagnostics
The study’s findings suggest that the Taiwan-made LensHooke® X1 PRO delivers consistent and reliable results comparable to manual analysis, and performs well under specific clinical conditions.

This indicates strong potential for X1 PRO to serve as a trusted alternative in clinical semen diagnostics, enhancing workflow efficiency and reducing subjectivity in fertility assessments.

The research team emphasized the need for further studies to validate X1 PRO’s full clinical value in the context of male fertility evaluation.

NUWA Fertility remains committed to advancing diagnostic technologies in reproductive medicine.
We continue to evaluate next-generation CASA systems, such as LensHooke® X1 PRO, to provide patients with more accurate, efficient, and comprehensive male fertility assessment services.
2025.07.03
2023 Academic Publications
TSRM 2023: For Non-Male Factor Infertility, Conventional IVF Performs Similarly to ICSI
Presented by NUWA Fertility at the 2023 Taiwan Society for Reproductive Medicine (TSRM)

At the 2023 TSRM annual meeting, NUWA Fertility presented a study comparing conventional in vitro fertilization (IVF) with intracytoplasmic sperm injection (ICSI) in couples with non-male factor infertility.

The research found no significant differences between the two fertilization methods across multiple embryo development indicators.

Background: Choosing a Fertilization Method in Non-Male Factor Infertility

In IVF treatment for couples with non-male factor infertility, whether ICSI should be routinely used remains a debated topic.

This study aimed to provide clarity by analyzing sibling oocytes from the same patient cohort, dividing them into two groups—one fertilized using conventional IVF, and the other using ICSI—to compare embryonic development outcomes.

Key Objective: Compare ICSI and IVF outcomes using sibling oocytes in couples without male infertility factors.

Study Results: IVF and ICSI Show Similar Outcomes in Non-Male Factor Cases
For couples without male factor infertility, the study compared outcomes between conventional IVF and ICSI using the same batch of eggs. The indicators assessed included:
2PN (Two-Pronuclei) Rate – marker of normal fertilization
Day 5 Blastocyst Formation Rate
Total Blastocyst Formation Rate
Top-Quality Embryo Rate
Euploidy Rate (based on PGS results)
The findings showed no statistically significant differences across all parameters.
This clearly suggests that routine use of ICSI in non-male factor cases does not provide additional benefit over conventional IVF.

Clinical Significance: Conventional IVF Can Be a Preferred First-Line Approach

The key conclusion of this study is that for patients without male factor infertility, ICSI offers no clear clinical advantage over traditional IVF.

In such cases, conventional IVF—which more closely mimics natural fertilization—may be considered the preferred first-line option. This approach could reduce both treatment costs and unnecessary invasive procedures.

NUWA Fertility is committed to providing individualized treatment strategies based on the latest clinical research.

For patients with non-male factor infertility, we carefully assess each case and engage in open, informed discussions to determine the most suitable and effective fertilization method—ultimately improving IVF outcomes and supporting every couple’s journey toward parenthood.
2025.07.01
2023 Academic Publications
Rethinking Hyaluronic Acid Concentration in Embryo Transfer Media and Its Impact on Implantation Rates
Presented by NUWA Fertility at the 2023 Taiwan Society for Reproductive Medicine (TSRM)

At the 2023 TSRM annual meeting, NUWA Fertility presented an oral research study investigating the relationship between hyaluronic acid (HA) concentration in embryo transfer media and implantation rates during frozen embryo transfer (FET) cycles. The study challenges the long-held assumption that higher concentrations of HA significantly improve implantation outcomes.

Background: The Role of Hyaluronic Acid in Embryo Implantation
Hyaluronic acid (HA) is commonly added to embryo transfer media due to its viscosity-enhancing and cell-adhesion-promoting properties, which are thought to facilitate better interaction between the embryo and the endometrium, potentially improving implantation success.

However, existing research remains inconclusive regarding the optimal HA concentration. This study aimed to determine whether varying concentrations of HA in transfer media have a significant impact on implantation rates in frozen embryo transfer cycles.

Key Insight: Higher HA concentration in transfer media does not necessarily correlate with improved implantation outcomes.

Study Findings: No Significant Correlation Between HA Concentration and Implantation Rate
The research team analyzed FET cycles using transfer media with different HA concentrations.
Results showed no significant difference in implantation rates between groups using low versus high concentrations of HA. This suggests that simply increasing the HA content in transfer media may not effectively enhance implantation success for frozen embryos.

Further Analysis: The Role of Post-Thaw Culture Duration
The study also examined whether the length of post-thaw embryo culture time influenced implantation outcomes.

In the low-HA group, extending culture time did not significantly improve implantation rates.

In the high-HA group, a slight trend toward higher implantation rates was observed with extended culture time—but this trend did not reach statistical significance and requires further validation in larger studies.

Clinical Implications: A More Balanced Perspective on HA Use in Embryo Transfer

These findings encourage both clinicians and patients to adopt a more evidence-based and cautious approach to the use of HA in embryo transfer media.

Pursuing higher HA concentrations alone may not be the key factor in improving frozen embryo implantation outcomes.

Future studies are needed to better understand the biological mechanisms of HA in implantation, explore potential individual patient differences, and establish evidence-based guidelines to guide clinical practice in embryo transfer preparation.

NUWA Fertility remains dedicated to advancing embryo transfer technologies and optimizing IVF outcomes.

By grounding clinical decisions in rigorous scientific research, we aim to provide patients with the most effective, individualized fertility care possible.
2025.06.25
2023 Academic Publications
CHLOE: The AI-Powered Embryo Scoring System That’s Revolutionizing Live Birth Outcomes in IVF
Presented by NUWA Fertility at the 2023 American Society for Reproductive Medicine (ASRM)

At the 2023 ASRM annual meeting, NUWA Fertility presented a groundbreaking study demonstrating the exceptional performance of the AI-powered embryo scoring system CHLOE in predicting live birth outcomes following day-5 single embryo transfers. This represents a major step forward in improving IVF success rates worldwide.

Background: Objective Embryo Assessment to Improve Live Birth Potential

In IVF treatment, selecting the embryo with the highest potential to result in a live birth is critical to success. Traditional embryo grading methods rely heavily on subjective morphological evaluations made by embryologists, which can vary between practitioners.

To improve accuracy and consistency, AI-based embryo evaluation systems have been developed. This study aimed to assess the effectiveness of the CHLOE scoring system in predicting live birth rates after single blastocyst transfers—and to compare its performance with that of the well-known KIDScore system.

CHLOE provides a more objective, standardized method for assessing embryo quality, improving accuracy and efficiency in embryo selection.

Results: Strong Positive Correlation Between CHLOE Scores and Live Birth Outcomes

The study revealed a significant positive correlation between CHLOE scores and live birth rates following day-5 single embryo transfers.
In other words, the higher the CHLOE score, the greater the likelihood that the embryo would successfully result in a healthy newborn.

Even more impressively, the data showed that CHLOE may outperform KIDScore in predicting pregnancy outcomes—suggesting that CHLOE may offer superior accuracy in identifying the most viable embryos.

Clinical Significance: CHLOE Leads the Way in Precision Embryo Selection
The study concludes that the AI-based CHLOE scoring system delivers more objective and standardized embryo evaluations, significantly enhancing both the accuracy and efficiency of embryo selection.
With CHLOE’s support, embryologists can more confidently identify the single embryo with the highest live birth potential, helping increase overall IVF success rates and bring more hopeful parents closer to their dream of having a healthy baby.

NUWA Fertility remains committed to adopting cutting-edge technologies that advance clinical outcomes in assisted reproduction.

By integrating the CHLOE AI embryo scoring system into clinical practice, we aim to further enhance our embryo selection strategies—delivering higher-quality, more efficient, and more personalized IVF care that drives higher live birth success rates.
2025.06.23

Request an Appointment

Consultation